- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Trident Texofab Limited has announced a board meeting to discuss the financial results for the quarter and half-year. The company continues to focus on its manufacturing operations, which drove 63.6% of revenue in FY25, with trading making up the remainder. Revenue grew 27% year-on-year in Q4FY25 to ₹38.2 Cr and 23% for FY25 to ₹122 Cr. EBITDA margins moderated to 4.48% in FY25 from 6.19% in FY24, impacted by rising costs despite the revenue growth. Manufacturing remains the core strength, supported by recent capacity expansions and capital infusion to pursue growth opportunities.